Needham & Company Reiterates Biogen (BIIB) at Buy Ahead of CMS Decision, but Notes It's Hard to Predict
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
